Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 10/20 | 0.52 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689315 | 1.00 | TLR4 (0.52) | TLR4LY96LMNAKMT2AMAPT | |
| SCHEMBL2336007 | 1.00 | TLR4 (0.52) | TLR4LY96LMNAKMT2AMAPT | |
| SCHEMBL12391273 | 1.00 | TLR4 (0.52) | TLR4LY96LMNAKMT2AMAPT | |
| SCHEMBL21138007 | 0.93 | TLR4 (0.55) | TLR4LY96LMNAKMT2AMAPT | |
| SCHEMBL12391272 | 0.90 | TLR4 (0.54) | TLR4LY96LMNAKMT2ATGM2 | |
| SCHEMBL12391271 | 0.88 | TLR4 (0.65) | TLR4LY96LMNAKMT2A | |
| SCHEMBL17793805 | 0.88 | TLR4 (0.65) | TLR4LY96LMNAKMT2A | |
| SCHEMBL2338181 | 0.88 | TLR4 (0.65) | TLR4LY96LMNAKMT2A | |
| SCHEMBL3336078 | 0.88 | LMNA (0.54) | TLR4LY96LMNAKMT2AMAPT | |
| SCHEMBL3336077 | 0.88 | LMNA (0.54) | TLR4LY96LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140220630-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220630-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | TLR4 704/4885LY96 4540/4885LMNA 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.